-
Bergenin Targets γδT17 Cells in Psoriasis
2026-09-17
A 2026 Phytomedicine study identifies a PPARγ–PROX1 pathway through which bergenin suppresses pathogenic γδT17-cell activity and IL-17A production in psoriasis models. Its combination of metabolic, ubiquitination, chromatin, and adoptive-transfer experiments provides a mechanistic framework for evaluating plant-derived immunometabolic interventions.
-
NSD1–PPARγ Methylation Rewires EC Glycolysis
2026-09-17
The reference study identifies a nonhistone methylation pathway in which NSD1 modifies PPARγ at K98, promotes its nuclear localization, and increases PTEN transcription. The resulting NSD1–PPARγ–PTEN axis restrains glycolysis and malignant behavior in endometrial cancer, while PTEN restoration or AKT inhibition can reverse phenotypes associated with NSD1 loss.
-
HBoV1 NS1–DNMT1 Control of Replication and RNA Processing
2026-09-16
The reference study identifies a coordinated epigenetic mechanism in which DNMT1-supported methylation promotes human bocavirus 1 DNA replication while restraining viral RNA processing. It further shows that the viral NS1 protein drives DNMT1 degradation through the ubiquitin–proteasome pathway, linking replication control with splicing, polyadenylation, protein expression, and NS1 nuclear localization.
-
Isoprinosine C4417: Reliable Assay Design
2026-09-16
This scenario-driven guide explains how Isoprinosine (SKU C4417) can support better-controlled viability, proliferation, and antiviral assays. It connects formulation data with HSV-1 nuclear-egress biology, practical controls, and vendor-selection criteria for more interpretable immunotherapy research.
-
BKT140: A CXCR4 Antagonist for Translational Assays
2026-09-15
BKT140, also known as BL-8040, enables a functional approach to CXCR4 biology across tumor-cell migration, apoptosis, and hematopoietic stem cell mobilization. This assay-centered guide connects receptor mechanism, molecular imaging, and experimental design for more informative oncology studies.
-
Carfilzomib (PR-171) in Cancer Research
2026-09-15
Carfilzomib (PR-171) is an irreversible proteasome inhibitor for connecting proteostasis failure with apoptosis, paraptosis, and ferroptosis in cancer models. This workflow shows how to combine proteasome activity measurements, ER-stress readouts, and radiation-response assays while avoiding common solvent, timing, and interpretation errors.
-
Escitalopram: From SSRI Target to Assay Design
2026-09-14
Explore how Escitalopram and Lexapro function as research tools for transporter pharmacology, serotonergic signaling, and phenotype interpretation. This guide connects molecular selectivity with lessons from a clinical moderator analysis to improve assay design.
-
Isoprenaline and the Heart–Brain Axis
2026-09-14
Isoprenaline Hydrochloride is more than a cardiac stimulant: it can serve as a mechanistic bridge between β-adrenergic signaling, cardiac physiology, vagal communication, and brain-state regulation. This thought-leadership guide translates recent PTSD-model findings into practical strategies for cardiovascular, neurobehavioral, and translational research.
-
Cyclopamine: From Hh Biology to Assay Design
2026-09-13
Cyclopamine is a Hedgehog signaling inhibitor with applications spanning cancer research, developmental biology, and mechanism-focused assay design. This guide connects product handling and phenotype selection with recent APOC1–cyclopamine findings in papillary thyroid carcinoma.
-
BIBP 3226: Mapping the NPY/NPFF Translational Axis
2026-09-12
A translational perspective on how BIBP 3226 trifluoroacetate can connect NPY Y1 and NPFF receptor pharmacology with adipose–neural signaling, cardiac arrhythmia, anxiety research, and analgesia mechanism study.
-
Rocilinostat: From HDAC6 Selectivity to Translation
2026-09-11
Rocilinostat (ACY-1215) offers a selective HDAC6 research strategy for multiple myeloma, with mechanistic readouts centered on α-tubulin acetylation, tumor-cell survival, and proteasome-inhibitor combinations. This article connects those oncology findings with new questions raised by SMPD4-dependent cilia and neurodevelopment research while defining the limits of that cross-domain interpretation.
-
BGJ398 Workflows for FGFR Research
2026-09-11
Build reproducible BGJ398 experiments for FGFR-dependent cancer models, pathway mapping, and carefully controlled developmental assays. Practical dosing, readout selection, and troubleshooting guidance help distinguish true FGFR biology from solubility, vehicle, and model-specific artifacts.
-
Linarin Drives NSCLC Arrest via Cyclin A2 Downregulation
2026-09-10
A 2026 study identifies the Herba Patriniae component linarin as an inhibitor of non-small-cell lung cancer cell growth, linking G0/G1 arrest, senescence, and apoptosis to reduced Cyclin A2, Cyclin B1, and CHEK1 signaling. Its combination of network pharmacology, EdU-based proliferation analysis, cell-cycle profiling, and molecular validation provides a useful framework for interpreting how herbal constituents may affect cancer-cell proliferation independently of p53 status.
-
Oltipraz Workflow for Nrf2 and Detoxification Assays
2026-09-10
Use Oltipraz as a defined Nrf2-pathway perturbation for phase II enzyme, oxidative-stress, and ferroptosis-related assay development. This workflow translates mechanistic insights from MASLD research into practical concentration, sampling, control, and troubleshooting strategies without treating a complex botanical intervention as equivalent to a single compound.
-
PKH26 Red Fluorescent Cell Linker Kit Guide
2026-09-09
The PKH26 Red Fluorescent Cell Linker Kit provides stable red labeling of cell-membrane lipid regions for cell tracing and proliferation-oriented assays in vitro and in vivo. It should not be used for intracellular targets or non-membrane structures, and exact labeling conditions require optimization for the cell model.